Express Pharma

2021 is a key year for personalised neoantigen immuno-oncology therapeutics: GlobalData

The four molecules expected to launch first, autogene cevumeran, GRANITE-001, ATL001, and Genocea Biosciences’ GEN-009 have combined peak forecast sales of over $1 billion by 2027